Endoluten: clinical report on a tissue-derived preparation
Comparison in people · 2011
- What was studied
- 163 patients: 99 adjunctive Endoluten; 64 controls across four diagnostic subgroups.
- Main finding
- In the dyshormonal myocardial dystrophy subgroup, estradiol was 101.3 pmol/L after Endoluten and 79.1 pmol/L after usual care. The report assessed several diagnoses separately.
Estradiol in the dyshormonal myocardial dystrophy subgroup · 101.3 ± 7.2 pmol/L with Endoluten versus 79.1 ± 4.2 pmol/L with conventional care. Shared baseline 65.4 ± 5.2 pmol/L. · Table 2 marks p < 0.05 versus conventional care.
Reported findings and study design
163 patients across four diagnoses, 99 receiving adjunctive Endoluten and 64 conventional care. Courses were one to three capsules two to three times daily for 15–30 days.
Population or model 163 patients: 99 adjunctive Endoluten; 64 controls across four diagnostic subgroups.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Estradiol in the dyshormonal myocardial dystrophy subgroup | 101.3 ± 7.2 pmol/L with Endoluten versus 79.1 ± 4.2 pmol/L with conventional care. Shared baseline 65.4 ± 5.2 pmol/L. | Table 2 marks p < 0.05 versus conventional care. |
| Follicle-stimulating hormone in the same subgroup | 46.8 ± 3.9 versus 71.6 ± 6.3 IU/mL, in the source’s printed units. Shared baseline 89.3 ± 3.5. | Table 2 marks p < 0.05 versus conventional care. |
The subgroup outcomes are short-term hormone measurements. The report does not explain the allocation method.
Source for these results ↗ · Reviewed 2026-11-16
Study limitations and source details
Study limitations
- Subgroups must not be pooled into one efficacy result. This oral-preparation report cannot inherit long-term Epithalamin mortality findings. The linked page commercially reproduces the report.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source details
Institute report — commercial reproduction
Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Sources checked
Citation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution). Endoluten: clinical report on a tissue-derived preparation Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date